Literature DB >> 2553256

Evaluation of the cocarcinogenic effect of wounding in Rous sarcoma virus tumorigenesis.

M H Sieweke1, A W Stoker, M J Bissell.   

Abstract

Chickens given injections of Rous sarcoma virus form sarcomas at the site of inoculation (primary tumor) and at the site of experimentally introduced wounds (wound tumor). This latter finding provides a model system to study systematically the mechanisms underlying the cocarcinogenic effects of wounding. Our experiments show the following. (a) Chickens inoculated with a Rous sarcoma virus-derived, replication-defective virus construct fail to elaborate wound tumors in spite of aggressively growing primary tumors. We thus rule out metastasis as a mechanism and conclude that infectious virus is required for wound tumor formation; (b) using bromodeoxyuridine incorporation and immunofluorescence on frozen sections we demonstrate proliferation in the unwounded wing in cell types which are normally targets for Rous sarcoma virus infection and transformation and conclude that proliferation per se is not sufficient to induce wound tumors; (c) using immunohistochemistry for the viral protein p19gag we show that wounding induces virus expression in fibroblasts of newly forming granulation tissue 2 days after injury. We also demonstrate expression of viral mRNA in wound tumors by in situ hybridization with a v-src probe. We discuss the possibility of activation of integrated, silent virus or the preferential infection of a special target cell population as a result of wounding as well as the potential role of wound factors in transformation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553256

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases.

Authors:  Paola Nisticò; Mina J Bissell; Derek C Radisky
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

2.  Tumor formation initiated by nondividing epidermal cells via an inflammatory infiltrate.

Authors:  Esther N Arwert; Rohit Lal; Sven Quist; Ian Rosewell; Nico van Rooijen; Fiona M Watt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 3.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

4.  Chemical carcinogenesis: too many rodent carcinogens.

Authors:  B N Ames; L S Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 5.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

6.  Rethinking carcinogenesis: The detached pericyte hypothesis.

Authors:  Stuart G Baker
Journal:  Med Hypotheses       Date:  2020-06-30       Impact factor: 1.538

7.  Transgenic overexpression of transforming growth factor alpha bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis.

Authors:  R Vassar; M E Hutton; E Fuchs
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

8.  Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression.

Authors:  Kathleen C Flanders; Lalage M Wakefield
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-04-25       Impact factor: 2.673

9.  The 9E3 protein: immunolocalization in vivo and evidence for multiple forms in culture.

Authors:  M Martins-Green; A Aotaki-Keen; L M Hjelmeland; M J Bissell
Journal:  J Cell Sci       Date:  1992-03       Impact factor: 5.285

10.  Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.

Authors:  Kevin N Woodward
Journal:  ISRN Vet Sci       Date:  2011-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.